Assessment of Onset, Safety & Toleration of UK-369,003 in Male Erectile Dysfunction

Pfizer

Status and phase: Completed; Phase 2

Conditions: Impotence

Treatments: Drug: UK-369,003

Study type: Interventional

Funder types: Industry

Identifiers

NCT00141349

A3711029

Details and patient eligibility

About

To determine the onset of action, safety and toleration of different formulations and doses of UK-369,003 in patients with erectile dysfunction. Patients should have been previously treated with PDE5 inhibitors and have been responders to the drugs. Duration of treatment is 4 weeks.

Sex: Male

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Erectile dysfunction as defined by DSM-IV. Patients should have been PDE5 inhibitor respondents

Exclusion criteria

• Alpha blockers and Nitrates of any preparation

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind